Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Higher vs standard starting dose of insulin glargine in overweight/obese newly diagnosed type 2 diabetes
ChiCTR-IIR-17011018Phase 4Not yet recruiting
- Sponsor
- Shenzhen Second People's Hospital
- Start
- Mar 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised trial of insulin glargine in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Shenzhen Second People's Hospital. Primary endpoints: fasting glucose success rate and hypoglycemia. Planned start Mar 2017; status: not yet recruiting.
02
Drugs
insulin glargine
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR-IIR-17011018.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IIR-17011018.